StockData
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. (NVCT) stock

NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.11−1.13 (-5.58%)

Close on Nov 16, 2026Market cap $622.63MP/E –Yield 0.00%

Nuvectis Pharma r&d expenses

Research and development expenses are spending on new products and technology.

Nuvectis Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $19.65M, up 34.5% year over year. For fiscal 2025 it was $18.15M, up 40.5% from the year before. The highest annual figure on record is $18.15M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.15M+40.5%
FY2024Dec 31, 2024$12.92M-16.0%
FY2023Dec 31, 2023$15.38M+16.3%
FY2022Dec 31, 2022$13.23M+38.6%
FY2021Dec 31, 2021$9.55M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.68M+29.6%
Q1 FY2026Mar 31, 2026$4.11M+11.6%
Q4 FY2025Dec 31, 2025$5.09M+13.1%
Q3 FY2025Sep 30, 2025$5.77M+104.8%
Q2 FY2025Jun 30, 2025$3.61M+22.8%
Q1 FY2025Mar 31, 2025$3.68M+38.3%
Q4 FY2024Dec 31, 2024$4.50M+5.4%
Q3 FY2024Sep 30, 2024$2.82M-37.2%
Q2 FY2024Jun 30, 2024$2.94M-30.9%
Q1 FY2024Mar 31, 2024$2.66M+12.4%
Q4 FY2023Dec 31, 2023$4.27M-3.0%
Q3 FY2023Sep 30, 2023$4.49M-0.8%
Q2 FY2023Jun 30, 2023$4.26M+70.1%
Q1 FY2023Mar 31, 2023$2.37M+31.1%
Q4 FY2022Dec 31, 2022$4.40M+284.4%
Q3 FY2022Sep 30, 2022$4.52M+8.8%
Q2 FY2022Jun 30, 2022$2.51M-41.0%
Q1 FY2022Mar 31, 2022$1.81M–
Q4 FY2021Dec 31, 2021$1.14M–
Q3 FY2021Sep 30, 2021$4.16M–
Q2 FY2021Jun 30, 2021$4.25M–

More Nuvectis Pharma figures

See a number that looks wrong?